Outlook Therapeutics Inc (OTLK)

[thermo]

Approved earlier this year:

On February 7, 2022, FDA had approved Vabysmo (faricimab-svoa), an injectable therapy for those with wet age-relate macular degeneration (wAMD) and diabetic macular edema. This approval is especially interesting considering that it is the first drug of its kind to be approved for both wAMD and diabetic macular edema.

As I noted, this will be a premium priced product, no different than Eylea.